基于Imidazoquinoline的新型TLR7激动剂诱导抗莱什曼疗效-一个体外研究
Shivani Thakur1, Kushvinder Kumar2, Sandeep Kaur1
1Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India.
Drug development research
|February 16, 2026
概括
新的托尔类受体 (TLR) - 7激动剂在治疗内脏莱什曼病 (VL) 中表现有前途. 化合物7及其体配方18表现出强大的抗莱什曼性活性,阻止寄生虫细胞循环并增加活性氧物种 (ROS).
科学领域:
- 免疫学 免疫学 免疫学
- 寄生虫学的寄生虫学
- 药用化学 医学化学
背景情况:
- 由于缺乏有效和安全的治疗方法,莱什曼病的控制受到阻碍.
- 开发新型抗莱什曼病药物是一个关键的全球卫生优先事项.
研究的目的:
- 评估基于伊米达佐基诺林的托尔类受体 (TLR) - 7激动剂作为潜在的抗莱什曼药物.
- 为了确定用于内脏莱什曼病 (VL) 治疗的化合物.
主要方法:
- 对TLR7激动剂库进行选,以检测对实验性VL的抗莱什曼疗效.
- 评估化合物对Leishmania donovani细胞周期进展的影响.
- 测量治疗寄生虫中的反应性氧物种 (ROS) 生成.
主要成果:
- 化合物7及其体配方18与米尔特福辛相比,显示出更高的活性.
- TLR7激动剂在亚G0/G1阶段捕获了较高比例的寄生虫.
- 对TLR7主动剂的治疗显著增加了莱什马尼亚寄生虫的ROS水平.
结论:
- 基于伊米达佐奎诺林的TLR7激动剂,特别是化合物7及其阴osomal配方18,是新型VL药物开发的有希望的候选者.
- 进一步的体内研究是有必要的,以推进这些化合物的临床应用.
关键词:
CC50 CC50 CC50 CC50 CC50 CC50 CC50 CC50 CC50 CC50 CC50IC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50 IC50这是TLR7激动剂.细胞循环停止 细胞循环停止尼奥索姆形成的配方药用药物 imidazoquinoline 是一种药物.有活性氧物种的反应性氧物种.更多相关视频
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.6K
06:57In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
8.7K
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
